IP AUSTRALIA
AUSTRALIAN PATENT OFFICE
Southern Cross Pharma Ltd v Euro-Celtique S.A. [2016] APO 1
Patent No.:2002300863, 2004229058, 2009243527
Title:Controlled Release Formulation
Patentee: Euro-Celtique S.A.
Opponent: Southern Cross Pharma Pty Ltd
Hearing Officer: Dr B. Akhurst
Decision Date: 8 January 2016 (Corrected on 21 January 2016)
Hearing Date: 1 December 2015
Catchwords: PATENTS – extensions of term – s 71(1)(c)/reg 6.8(3) – the substance as it occurs in the goods – insufficient information where the amount of an ingredient is provided as a broad range –s 71(1)(c)/reg 6.8(2) – no information provided showing that the listed goods have a required polymer content – insufficient information to show that a relevant goods is listed on the ARTG –s 70(3)(a) – insufficient information to establish that the listed goods do in fact contain, or consist of, a pharmaceutical substance falling within the scope of the claims of two patents – opportunity provided to file further information under reg 6.11
Representation: Patentee: Philip Kerr, solicitor, and Linda Govenlock of Allens Patent & Trade Mark Attorneys, Sydney.
Opponent: Kate Beattie of counsel
IP AUSTRALIA
AUSTRALIAN PATENT OFFICE
Patent Nos.:2002300863, 2004229058, 2009243527
Title:Controlled Release Formulation
Patentee: Euro-Celtique S.A.
Date of Decision: 8 January 2016 (Corrected on 21 January 2016)
DECISION
The opposition to grant of an extension of the term of patent 2004229058 is unsuccessful. Costs for this opposition are awarded according to Schedule 8 against Southern Cross.
The oppositions to grant of an extension of the term of patents 2002300863 and 2009243527 are successful. Costs in these oppositions are awarded according to Schedule 8 against Euro-Celtique S.A.
Pursuant to reg 6.11, the patentee has two (2) months from the date of this decision to provide further information as follows:
(i) for the 2009243527 patent, more precise information regarding the weight for weight proportions (% w/w) of cellulose ether and polyalkylene glycol(s) as these occur in the goods TRAMAL®SR 100, and
(ii) for the 2002300863 patent, precise information regarding the weight for weight proportion (% w/w) of hydrophilic or hydrophobic polymer(s) as these occur in the goods TRAMAL®SR 100.
At the end of that period the oppositions to an extension of term for patents 2002300863 and 2009243527 will be finally determined.
REASONS FOR DECISION
Background
This opposition relates to applications by Euro-Celtique S.A. (the patentee) to extend the term of three related patents - 2002300863 (‘863), 2004229058 (‘058) and 2009243527 (‘527). The original standard patent application 61963/94, and serial divisionals 39957/97 and 65526/99, lapsed without gaining acceptance. Patent ‘863 is a divisional of 65526/99. Patents ‘058 and ‘527 are both divisionals of patent ‘863. Patent application ‘527 was granted on 20 March 2014 after Sandoz Pty Ltd withdrew its opposition to grant of a patent. Patent applications ‘863 and ‘058 were granted on 6 May 2014 after Federal Court appeals by Sandoz Pty Ltd. under s 60(4) of the Patents Act 1990 (the Act) were discontinued. The date of these patents is 9 May 1994 and their…
Keep reading for free
Create a free CaseChat account to read Southern Cross Pharma Ltd v Euro-Celtique S.A. and more:
- Read every judgment in full
- Ask AI and get answers linked to paragraphs
- See how each paragraph was cited in later cases
- Download judgments as PDF or Word
One click creates your free account or signs you in.
By continuing you agree to the Terms and Privacy Policy.
- Case
- [2016] APO 1
- Decision Date
CaseChat Overview and Summary
Background
Background to the litigation
The matter came before the Australian Patent Office as an opposition to the grant of an extension of the term of the three patents. The Commissioner accepted the applications for an extension of term on 26 May 2014, and the matter was advertised on 12 June 2014. Southern Cross Pharma Pty Ltd filed notices opposing the grant of the extensions on 10 September 2014, followed by statements of grounds and particulars (SGP) on 10 December 2014. Evidence in support, answer, and reply were filed on 10 March 2015, 10 June 2015, and 17 August 2015, respectively. The matter was heard in Canberra on 1 December 2015.
Decision
Reasons for decision
1. Are the applications for an extension of term of patents '863 and '527 deficient in that they do not provide sufficient information regarding the weight for weight proportion (% w/w) of cellulose ether and polyalkylene glycol(s) as they occur in the goods TRAMAL®SR 100?
2. Are the applications for an extension of term of patents '863 and '527 deficient in that they do not provide information showing that goods containing, or consisting of, the pharmaceutical substance are currently included in the Australian Register of Therapeutic Goods?
3. Are the applications for an extension of term of patents '863 and '527 deficient in that they do not provide sufficient information to show that a goods containing or consisting of a pharmaceutical substance falling within claim 1 of the '863 or '527 patent is currently included in the ARTG?
Held
1. The application for an extension of term of patent 2004229058 is unsuccessful.
2. The application for an extension of term of patents 2002300863 and 2009243527 is successful on the grounds that the applications are deficient under sections 70(3)(a) and 71(1)(c) of the Patents Act 1990. However, the court will give the patentee an opportunity to provide further information to overcome the deficiencies.
3. Costs are awarded according to Schedule 8, with Southern Cross Pharma Pty Ltd successful in two oppositions and unsuccessful in the third, and Euro-Celtique S.A. ordered to pay costs for the successful oppositions.
Ratio Decidendi
Legal Principle Established
The court considered the applications for an extension of term for three patents, determining whether the applications were deficient under sections 70(3)(a) and 71(1)(c) of the Patents Act 1990. For patents 2002300863 and 2009243527, the court found the applications deficient because they did not provide sufficient information regarding the weight for weight proportion of cellulose ether and polyalkylene glycol(s) as they occur in the goods TRAMAL® SR 100, and they did not provide information showing that goods containing, or consisting of, the pharmaceutical substance are currently included in the Australian Register of Therapeutic Goods (ARTG). However, the court noted that these deficiencies could potentially be overcome with further information, and therefore gave the patentee an opportunity to provide such information under regulation 6.11. The application for patent 2004229058 was found to be sufficient, and the opposition to it was unsuccessful. The court also addressed the standard of proof and the onus of proof in the opposition proceedings, concluding that the onus of proof lies with the opponent to establish their grounds of opposition. Finally, the court awarded costs according to Schedule 8, with the losing party in each opposition ordered to pay the costs of the winning party.